Created in 2013 by Prof. Sebastien Gibot, Dr. Marc Derive and Dr. Jean-Jacques Garaud, Inotrem is a French biotech company specializing in the discovery and development of novel treatments in the field of inflammatory pathologies with a focus on critical care.
The Company’s leading product candidate is a TREM-1 inhibitor that aims to control excessive inflammation in severe sepsis patients.
Since its inception Inotrem has received the initial support of the Incubateur Lorrain and the University of Lorraine in Nancy, Région Lorraine, BPI France and Inserm Transfert.